About Caris Life Sciences
Caris Life Sciences is a publicly listed company based in Irving (United States) founded in 1996. Panomic profiling technologies are developed for cancer precision medicine. It operates on a AI-as-a-Service, Professional Services, and HealthTech model. Caris Life Sciences has raised $1.23 billion across 9 funding rounds from investors including Fidelity Investments, TPG and T. Rowe Price. The company has 61 employees. Caris Life Sciences has completed 1 acquisition, including Caris Life Sciences. Caris Life Sciences was last valued at $5.67 billion in June 2025. Its website carislifesciences.com draws about 38 thousand monthly visits. Caris Life Sciences offers products and services including Caris Assure, MI Profile, and Caris Molecular AI. Its focus areas include Biotechnology and Precision Medicine. Its competitors include Guardant Health, Natera and Denali Therapeutics; 3 of its 3 listed competitors have raised funding.
Company details
Caris Life Sciences is engaged in revolutionizing cancer care through precision medicine. The company is recognized for developing innovative solutions that analyze biological networks at the molecular level. Services are provided across the care continuum, including disease detection, therapy selection, and treatment monitoring. Advanced technologies in molecular profiling and AI are utilized to inform personalized treatment decisions. The healthcare sector is primarily served, with a focus on oncology. Comprehensive databases combining genomic, transcriptomic, and proteomic data with clinical outcomes are maintained. Solutions are offered to patients, physicians, and biopharma partners to improve patient outcomes globally.
- Headquarters Irving, United States
- Employees 61
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Phone•••• ••••
- Website carislifesciences.com
- Social LinkedIn X Facebook
- Legal Name Caris Life Sciences, Inc.
- Annual Revenue$812.03 M (USD)as on Dec 31, 2025
- Net Profit-$68.09 M (USD)as on Dec 31, 2025
- EBITDA$45.11 M (USD)as on Dec 31, 2025
- Total Equity Funding$1.23B (USD)
in 9 rounds
- Latest Funding Round$168M (USD), Series D
Apr 2025
- InvestorsFidelity Investments
& 21 more
- Employee Count61
- Investments & Acquisitions
Products & Services of Caris Life Sciences
Caris Life Sciences offers a comprehensive portfolio of products and services, including Caris Assure, MI Profile, and Caris Molecular AI.
Blood-based sequencing is used for deep molecular insights.
Tissue profiling is provided for comprehensive molecular blueprints.
AI solutions are applied for cancer classification insights.
Funding Insights of Caris Life Sciences
Caris Life Sciences has successfully raised a total of $1.23B across 9 strategic funding rounds. The most recent funding activity was a Series D round of $168 million completed in April 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $1.23B
- Total Rounds 9
- Last Round Series D — $168M
- First Round $248,273
(Jan 2017)
- Investors Count 22
All 9 funding rounds of Caris Life Sciences with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr 2025 | $168M | Series D | – | Braidwell | |
| Jan 2023 | Debt – Conventional | – | – | ||
| May 2021 | $830M | Series D | $7.83B | Sixth Street | |
| Oct 2020 | $235M | Series D | – | Coatue, Highland Capital Management | |
| Oct 2020 | $75M | Debt – Conventional | – | – | |
| Oct 2018 | Private Equity Round | – | – | ||
| Sep 2018 | Debt – Conventional | – | – | ||
| Sep 2017 | $303,653 | Grant | – | – | – |
| Jan 2017 | $248,273 | Grant | – | – |
| Date | Valuation | Stage |
|---|---|---|
| May 2021 | $7.83B | •••••••• |
Full valuation and stage history of Caris Life Sciences
Every valuation point, the growth-stage changes (minicorn, soonicorn, unicorn) and the dates behind them require an active premium plan.
- All valuation points
- Stage changes
- Dates
- Exports
Verified entity values are shown only after access is granted.
Last known valuation $5.67B (Jun 2025). 22 investors in total: 22 institutional.
Investors in Caris Life Sciences
Caris Life Sciences has secured backing from 22 investors, including institutional and venture fund investors. Prominent investors backing the company include Fidelity Investments, TPG and T. Rowe Price.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Health-tech companies are targeted for venture capital investments. | 1999 | perceptivelife.com | New York, United States | |
| firstlightam.com | ||||
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields. | 1989 | orbimed.com | New York, United States | |
Technology investing and private equity firm focused on partnerships. | silverlake.com | |||
Provider of an investment platform for various stages | coatue.com | New York, United States | ||
Secondary market fund focused on LP and direct secondary transactions | 1993 | nb.com | New York, United States | |
Private equity and debt investments are managed across multiple sectors. | sixthstreet.com | San Francisco, United States | ||
Fund of funds focused on pre-seed and seed-stage companies | 1992 | tpg.com | Fort Worth, United States | |
| whitney.com | ||||
Offers flexible capital and partnerships to companies in life sciences sectors. | braidwell.com |
Investor details for Caris Life Sciences
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Caris Life Sciences
511 people are tracked at Caris Life Sciences (186 in leadership, 13 in board & advisors, 312 in team); the tracked headcount is 61.
| Name | Role | Group |
|---|---|---|
Terry White | Corporate VP Of Commercial Strategy | Leadership |
Jim Abraham | SVP & Chief Digital Officer | Leadership |
Joanne Xiu | Vice President, Clinical And Translational Research | Leadership |
Chase G. Wasson | Vice President | National Partnerships | Leadership |
Matthew Oberley | Chief Clinical Officer | Leadership |
Milan Radovich | Senior Vice President And Chief Scientific Officer | Leadership |
Samantha Fowlkes | Vice President: Head - Precision Medicine | Account Implementation | Commercial & Lab Partnership | Leadership |
Farah Abdulla | Vp, Vice Chair Precision Oncology Alliance (poa) | Leadership |
Steven Rutkowski | Director Precision Medicine Initiatives | Leadership |
Brett Kimball | Director Precision Medicine Initiatives, Southeast Caris Life Sciences | Leadership |
Rebecca Feldman | Vice President, Biomarker And Drug Intelligence | Leadership |
Dan McDonald | Vice President - Precision Oncology Alliance | Leadership |
Wendy Greer | Vice President Human Resources | Leadership |
Greg Ash | Vice President, Strategic Account Management | Leadership |
Sharon Wu | Director, Clinical And Translational Research | Leadership |
Kim McLaughlin | Senior Director - Alliances | Leadership |
Tyler Shropshire | Vice President, Global Biopharma Business Development, Head Of Real World Data | Leadership |
Brady Gilg | Director Of Data Science | Leadership |
Siobhan Miick | Senior Director - Translational Science Companion Diagnostics | Leadership |
Luke Power | Chief Financial Officer | Leadership |
491 more people are available in the full profile.
Complete people profiles for Caris Life Sciences
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Caris Life Sciences
Caris Life Sciences is a publicly listed company on the NASDAQ with ticker symbol CAI in USA, operating in the Technology services sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date18 Jun 2025
- Listed onNASDAQ: CAI
- Listed entityCaris Life Sciences, Inc.
- Exchange sectorTechnology services
- ISINUS1421521071
- Share price$29.53 (-0.54% on the day) · 2026-10-13
- Market capitalisation$8.35B
- Price to earnings79.3
- EPS (diluted, trailing year)$0.37
- Volume (last session)3,524,026
Investments & Acquisitions by Caris Life Sciences
Caris Life Sciences has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Caris Life Sciences.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Oncology-focused CRO and SMO services are provided for clinical development. | pharmatech.com | Denver, United States | 1987 | May 2019 | •••• |
Complete acquisition details for Caris Life Sciences
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Caris Life Sciences
6 dated milestones of Caris Life Sciences across 29 years, from founding to its latest funding, stage changes and deals.
- Founded Caris Life Sciences is founded.
- Funding First funding round of $248K.
- Acquisition Acquires Caris Life Sciences.
- Milestone Reaches Unicorn status.
- Funding Latest funding round, Series D, of $168.0M.
- IPO Lists on the stock exchange (IPO).
Competitors of Caris Life Sciences
Caris Life Sciences has 3 listed competitors in our database, 3 of them funded. They include Guardant Health, Natera and Denali Therapeutics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| guardanthealth.com | 2012 | Redwood, United States | $557.5M | 1,351 | Digital sequencing technology for cancer detection is developed. | |
| natera.com | 2004 | Redwood, United States | $152.1M | 3,293 | Developer of cell-free DNA testing for oncology, women’s health, and organ health | |
| denalitherapeutics.com | 2015 | San Francisco, United States | $347M | 377 | Neurodegenerative disease therapies are developed for Alzheimer's, ALS, and Parkinson's. |
Detailed competitors of Caris Life Sciences
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Caris Life Sciences
The website of Caris Life Sciences (carislifesciences.com) receives about 38.2K visits a month and ranks #745,593 among all websites worldwide, #865 in Biotechnology and Pharmaceuticals.
- Monthly visits38.2K
▼ 14.3% vs previous month
- Unique visitors22.8K
per month
- Global rank#745,593
among all websites
- Category rank#865
Health · Biotechnology and Pharmaceuticals
- Bounce rate49%
- Pages per visit1.7
- Average visit25 sec
- DevicesDesktop 43% · Mobile 57%
Websites whose visitors overlap most with Caris Life Sciences. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| anavex.com | 100% | 23.1K | #1,188,295 | View details | |
miracalifesciences.com | miracalifesciences.com | 98% | – | ||
| carismolecularintelligence.com | 98% | #4,659,983 | View details | ||
astrazenecaclinicaltrials.com | astrazenecaclinicaltrials.com | 96% | #956,127 | – | |
| patheon.com | 96% | 89.1K | #488,648 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 23 similar websites and full traffic analytics for Caris Life Sciences
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 23 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as Caris Life Sciences (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Caris Life Sciences
Complete news archive for Caris Life Sciences
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Caris Life Sciences
Caris Life Sciences was founded in 1996 and raised its 1st funding round 21 years after it was founded.
Caris Life Sciences is headquartered in Irving, United States. It is registered at Irving, Texas, United States.
Caris Life Sciences is a funded company, having raised a total of $1.23B across 9 funding rounds to date. The company's 1st funding round was a Grant of $248.27K, raised on Jan 2017.
Caris Life Sciences has 61 employees.
Annual revenue of Caris Life Sciences is $812.03M as on Dec 31, 2025.
Caris Life Sciences is engaged in revolutionizing cancer care through precision medicine. The company is recognized for developing innovative solutions that analyze biological networks at the molecular level. Services are provided across the care continuum, including disease detection, therapy selection, and treatment monitoring. Advanced technologies in molecular profiling and AI are utilized to inform personalized treatment decisions. The healthcare sector is primarily served, with a focus on oncology. Comprehensive databases combining genomic, transcriptomic, and proteomic data with clinical outcomes are maintained. Solutions are offered to patients, physicians, and biopharma partners to improve patient outcomes globally.
Caris Life Sciences's top competitors include Guardant Health, Natera and Denali Therapeutics.
Caris Life Sciences offers Caris Assure, MI Profile, and Caris Molecular AI.
Yes, Caris Life Sciences is publicly traded on NASDAQ under the ticker symbol CAI.
Caris Life Sciences has made 1 acquisition, including Caris Life Sciences.
Caris Life Sciences has 22 investors. Key investors include Fidelity Investments, TPG, T. Rowe Price, Orbimed, and CPP Investments.
The valuation of Caris Life Sciences is $5.67B as of Jun 2025.